The massive share issuance signals urgent capital needs, likely driven by cash burn from clinical programs. The option repricing 2 days prior suggests management was incentivized to push the offering through at any price. Watch for the Q3 2026 cash runway update and any clinical data readouts that could justify the dilution.
Price Chart
Executive Summary
Alector priced a dilutive underwritten offering of 36.6M shares at $2.05/share, raising ~$75M in gross proceeds. The offering comes 2 days after an option repricing for executives (including the CEO) and follows a period of significant stock decline. The massive ~33%+ dilution is a clear negative signal, partially offset by the cash infusion and participation from notable healthcare investors.
Key Financial Metrics
Key Facts
- Alector priced an underwritten offering of 36,600,000 shares of common stock at $2.05 per share.
- Gross proceeds expected to be approximately $75,030,000 before underwriting discounts and commissions.
- The offering price of $2.05 represents a premium of approximately 7.3% over the closing price on October 15, 2026.
- The offering is expected to close on October 19, 2026.
- New and existing investors participating include TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital.
- Net proceeds will be used for general corporate purposes, including R&D, manufacturing, working capital, and potential acquisitions.
- The offering was executed under a shelf registration statement (Form S-3, File No. 333-294241).
- Two days prior (October 13, 2026), the Board approved an option repricing for employees, including the CEO (2,421,197 options repriced to $1.87).
- The underwriters' purchase price is $1.927 per share.
Financial Impact
Dilution of approximately 33%+ based on 36.6M new shares vs. pre-offering outstanding shares. Gross proceeds of $75M provide cash runway but at significant shareholder cost.
Risk Factors
- Massive dilution (~33%+) will pressure the stock price as new shares hit the market.
- The offering suggests the company's cash runway was shorter than expected, raising questions about financial discipline.
- The option repricing just before the offering creates a misalignment with existing shareholders.
- Proceeds used for general corporate purposes, not a specific catalyst, making it a 'dilution for survival' signal.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424204 |
| Document: d417912d8k.htm | 0001193125-26-424204 |
| Document: d417912dex51.htm | 0001193125-26-424204 |
| Document: d417912dex991.htm | 0001193125-26-424204 |
| Document: 0001193125-26-424204-index-headers.html | 0001193125-26-424204 |
| Document: 0001193125-26-424204-index.html | 0001193125-26-424204 |
| Document: 0001193125-26-424204.txt | 0001193125-26-424204 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13G | $1.82 | awaiting T+60 | — | $2.10 (+15.38%) |
Oct 23, 2026 4d ago | SC 13G | $1.83 | awaiting T+60 | — | $2.10 (+14.75%) |
Oct 16, 2026 11d ago | 424B5 | $1.95 | awaiting T+60 | — | $2.10 (−7.69%) |
Oct 16, 2026 11d ago | 8-K | $1.95 | awaiting T+60 | — | $2.10 (−7.69%) |
Oct 14, 2026 13d ago | 8-K | $1.88 | awaiting T+60 | — | $2.10 (+11.70%) |
Oct 5, 2026 22d ago | 8-K | $1.99 | awaiting T+60 | — | $2.10 (+5.53%) |
Oct 5, 2026 22d ago | Press Release | $1.99 | awaiting T+60 | — | $2.10 (+5.53%) |
Sep 18, 2026 5w ago | SC 13G | $1.93 | awaiting T+60 | — | $2.10 (+8.81%) |
Sep 4, 2026 7w ago | Insider Cluster | $2.47 | awaiting T+60 | — | $2.10 (−14.98%) |
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 | awaiting T+60 | — | $2.10 (+2.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers